CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
Pegcetacoplandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03593200
NCT03593200Phase 2Completed
CompareCT.gov

Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).

Apellis Pharmaceuticals, Inc.·interventional·Posted Jul 20, 2018·Updated Dec 22, 2020

In Brief

A Phase 2 clinical trial evaluating Pegcetacoplan for PNH. Completed, enrolled 4 participants across 3 sites in 2 countries.

Detailed Summary

This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPNH
CountriesBulgaria, Serbia
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 20, 2018
Enrollment StartAug 16, 2018
Primary CompletionOct 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.0 years ago

Interventions

Pegcetacoplandrug

Complement (C3) Inhibitor